Do analysts rate FDMT or CYPH?

4D Molecular Therapeutics currently has a consensus price target of $29.88, indicating a potential upside of 245.78%. Given 4D Molecular Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe 4D Molecular Therapeutics is more favorable than Cypherpunk Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 4D Molecular Therapeutics 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.67 Cypherpunk Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate CYPH or ARVN?

Arvinas has a consensus target price of $15.42, indicating a potential upside of 115.62%. Given Arvinas' stronger consensus rating and higher probable upside, analysts clearly believe Arvinas is more favorable than Cypherpunk Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cypherpunk Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Arvinas 2 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.46

Which has higher valuation & earnings, KYTX or CYPH?

Cypherpunk Technologies is trading at a lower price-to-earnings ratio than Kyverna Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kyverna Therapeutics N/A N/A -$161.31M -$3.28 N/A Cypherpunk Technologies N/A N/A $4.82M -$0.02 N/A

Is KYTX or CYPH more profitable?

Cypherpunk Technologies' return on equity of -48.33% beat Kyverna Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Kyverna Therapeutics N/A -81.88% -64.87% Cypherpunk Technologies N/A -48.33% -42.21%

Do analysts rate CYPH or PRTA?

Prothena has a consensus target price of $23.75, suggesting a potential upside of 177.45%. Given Prothena's stronger consensus rating and higher possible upside, analysts plainly believe Prothena is more favorable than Cypherpunk Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cypherpunk Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Prothena 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.63

Do analysts prefer CTNM or CYPH?

Contineum Therapeutics presently has a consensus target price of $20.00, indicating a potential upside of 73.46%. Given Contineum Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Contineum Therapeutics is more favorable than Cypherpunk Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Contineum Therapeutics 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50 Cypherpunk Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is CTNM or CYPH more profitable?

Contineum Therapeutics' return on equity of -27.09% beat Cypherpunk Technologies' return on equity. Company Net Margins Return on Equity Return on Assets Contineum Therapeutics N/A -27.09% -25.64% Cypherpunk Technologies N/A -48.33% -42.21%

Cypherpunk Technologies (CYPH) Competitors

$0.71 +0.19 (+36.51%)

As of 06/8/2026 04:00 PM Eastern

Compare

CYPH vs. FDMT, ARVN, KYTX, PRTA, and CTNM

Should you buy Cypherpunk Technologies stock or one of its competitors? MarketBeat compares Cypherpunk Technologies with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cypherpunk Technologies include 4D Molecular Therapeutics (FDMT), Arvinas (ARVN), Kyverna Therapeutics (KYTX), Prothena (PRTA), and Contineum Therapeutics (CTNM). These companies are all part of the "pharmaceutical products" industry.

How does Cypherpunk Technologies compare to 4D Molecular Therapeutics?

4D Molecular Therapeutics (NASDAQ:FDMT) and Cypherpunk Technologies (NASDAQ:CYPH) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk, institutional ownership and media sentiment.

99.3% of 4D Molecular Therapeutics shares are owned by institutional investors. Comparatively, 30.5% of Cypherpunk Technologies shares are owned by institutional investors. 7.9% of 4D Molecular Therapeutics shares are owned by company insiders. Comparatively, 3.5% of Cypherpunk Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

4D Molecular Therapeutics has a beta of 2.75, suggesting that its share price is 175% more volatile than the broader market. Comparatively, Cypherpunk Technologies has a beta of -0.02, suggesting that its share price is 102% less volatile than the broader market.

Cypherpunk Technologies has lower revenue, but higher earnings than 4D Molecular Therapeutics. Cypherpunk Technologies is trading at a lower price-to-earnings ratio than 4D Molecular Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
4D Molecular Therapeutics	$85.21M	5.30	-$140.11M	-$2.57	N/A
Cypherpunk Technologies	N/A	N/A	$4.82M	-$0.02	N/A

Cypherpunk Technologies has a net margin of 0.00% compared to 4D Molecular Therapeutics' net margin of -182.34%. 4D Molecular Therapeutics' return on equity of -36.83% beat Cypherpunk Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
4D Molecular Therapeutics	-182.34%	-36.83%	-32.55%
Cypherpunk Technologies	N/A	-48.33%	-42.21%

In the previous week, 4D Molecular Therapeutics had 4 more articles in the media than Cypherpunk Technologies. MarketBeat recorded 4 mentions for 4D Molecular Therapeutics and 0 mentions for Cypherpunk Technologies. 4D Molecular Therapeutics' average media sentiment score of 0.21 beat Cypherpunk Technologies' score of 0.00 indicating that 4D Molecular Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
4D Molecular Therapeutics	Neutral
Cypherpunk Technologies	Neutral

4D Molecular Therapeutics currently has a consensus price target of $29.88, indicating a potential upside of 245.78%. Given 4D Molecular Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe 4D Molecular Therapeutics is more favorable than Cypherpunk Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
4D Molecular Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Cypherpunk Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

4D Molecular Therapeutics beats Cypherpunk Technologies on 12 of the 15 factors compared between the two stocks.

How does Cypherpunk Technologies compare to Arvinas?

Cypherpunk Technologies (NASDAQ:CYPH) and Arvinas (NASDAQ:ARVN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings, valuation and media sentiment.

30.5% of Cypherpunk Technologies shares are held by institutional investors. Comparatively, 95.2% of Arvinas shares are held by institutional investors. 3.5% of Cypherpunk Technologies shares are held by insiders. Comparatively, 7.3% of Arvinas shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Cypherpunk Technologies has a beta of -0.02, meaning that its share price is 102% less volatile than the broader market. Comparatively, Arvinas has a beta of 1.75, meaning that its share price is 75% more volatile than the broader market.

Cypherpunk Technologies has a net margin of 0.00% compared to Arvinas' net margin of -247.54%. Arvinas' return on equity of -44.38% beat Cypherpunk Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cypherpunk Technologies	N/A	-48.33%	-42.21%
Arvinas	-247.54%	-44.38%	-28.38%

Arvinas has a consensus target price of $15.42, indicating a potential upside of 115.62%. Given Arvinas' stronger consensus rating and higher probable upside, analysts clearly believe Arvinas is more favorable than Cypherpunk Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cypherpunk Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Arvinas	2 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.46

In the previous week, Arvinas had 7 more articles in the media than Cypherpunk Technologies. MarketBeat recorded 7 mentions for Arvinas and 0 mentions for Cypherpunk Technologies. Arvinas' average media sentiment score of 0.40 beat Cypherpunk Technologies' score of 0.00 indicating that Arvinas is being referred to more favorably in the news media.

Company	Overall Sentiment
Cypherpunk Technologies	Neutral
Arvinas	Neutral

Cypherpunk Technologies has higher earnings, but lower revenue than Arvinas. Cypherpunk Technologies is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cypherpunk Technologies	N/A	N/A	$4.82M	-$0.02	N/A
Arvinas	$262.60M	1.76	-$80.80M	-$3.32	N/A

Summary

Arvinas beats Cypherpunk Technologies on 12 of the 15 factors compared between the two stocks.

How does Cypherpunk Technologies compare to Kyverna Therapeutics?

Kyverna Therapeutics (NASDAQ:KYTX) and Cypherpunk Technologies (NASDAQ:CYPH) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, media sentiment, earnings, institutional ownership, risk, analyst recommendations and valuation.

Kyverna Therapeutics has a beta of 1.96, meaning that its stock price is 96% more volatile than the broader market. Comparatively, Cypherpunk Technologies has a beta of -0.02, meaning that its stock price is 102% less volatile than the broader market.

Cypherpunk Technologies' return on equity of -48.33% beat Kyverna Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kyverna Therapeutics	N/A	-81.88%	-64.87%
Cypherpunk Technologies	N/A	-48.33%	-42.21%

In the previous week, Kyverna Therapeutics had 5 more articles in the media than Cypherpunk Technologies. MarketBeat recorded 5 mentions for Kyverna Therapeutics and 0 mentions for Cypherpunk Technologies. Kyverna Therapeutics' average media sentiment score of 0.15 beat Cypherpunk Technologies' score of 0.00 indicating that Kyverna Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Kyverna Therapeutics	Neutral
Cypherpunk Technologies	Neutral

Kyverna Therapeutics currently has a consensus target price of $30.00, suggesting a potential upside of 289.11%. Given Kyverna Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Kyverna Therapeutics is more favorable than Cypherpunk Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyverna Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Cypherpunk Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Cypherpunk Technologies is trading at a lower price-to-earnings ratio than Kyverna Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyverna Therapeutics	N/A	N/A	-$161.31M	-$3.28	N/A
Cypherpunk Technologies	N/A	N/A	$4.82M	-$0.02	N/A

18.1% of Kyverna Therapeutics shares are held by institutional investors. Comparatively, 30.5% of Cypherpunk Technologies shares are held by institutional investors. 17.6% of Kyverna Therapeutics shares are held by insiders. Comparatively, 3.5% of Cypherpunk Technologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Kyverna Therapeutics beats Cypherpunk Technologies on 8 of the 13 factors compared between the two stocks.

How does Cypherpunk Technologies compare to Prothena?

Cypherpunk Technologies (NASDAQ:CYPH) and Prothena (NASDAQ:PRTA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends, risk and media sentiment.

Cypherpunk Technologies has higher earnings, but lower revenue than Prothena. Cypherpunk Technologies is trading at a lower price-to-earnings ratio than Prothena, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cypherpunk Technologies	N/A	N/A	$4.82M	-$0.02	N/A
Prothena	$9.68M	46.29	-$244.09M	-$2.82	N/A

30.5% of Cypherpunk Technologies shares are held by institutional investors. Comparatively, 97.1% of Prothena shares are held by institutional investors. 3.5% of Cypherpunk Technologies shares are held by company insiders. Comparatively, 10.4% of Prothena shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Prothena has a consensus target price of $23.75, suggesting a potential upside of 177.45%. Given Prothena's stronger consensus rating and higher possible upside, analysts plainly believe Prothena is more favorable than Cypherpunk Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cypherpunk Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Prothena	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.63

Cypherpunk Technologies has a beta of -0.02, suggesting that its share price is 102% less volatile than the broader market. Comparatively, Prothena has a beta of -0.25, suggesting that its share price is 125% less volatile than the broader market.

In the previous week, Prothena had 6 more articles in the media than Cypherpunk Technologies. MarketBeat recorded 6 mentions for Prothena and 0 mentions for Cypherpunk Technologies. Prothena's average media sentiment score of 1.30 beat Cypherpunk Technologies' score of 0.00 indicating that Prothena is being referred to more favorably in the news media.

Company	Overall Sentiment
Cypherpunk Technologies	Neutral
Prothena	Positive

Cypherpunk Technologies has a net margin of 0.00% compared to Prothena's net margin of -260.92%. Prothena's return on equity of -43.44% beat Cypherpunk Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cypherpunk Technologies	N/A	-48.33%	-42.21%
Prothena	-260.92%	-43.44%	-36.87%

Summary

Prothena beats Cypherpunk Technologies on 12 of the 16 factors compared between the two stocks.

How does Cypherpunk Technologies compare to Contineum Therapeutics?

Contineum Therapeutics (NASDAQ:CTNM) and Cypherpunk Technologies (NASDAQ:CYPH) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability and risk.

30.5% of Cypherpunk Technologies shares are held by institutional investors. 11.3% of Contineum Therapeutics shares are held by company insiders. Comparatively, 3.5% of Cypherpunk Technologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Contineum Therapeutics presently has a consensus target price of $20.00, indicating a potential upside of 73.46%. Given Contineum Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Contineum Therapeutics is more favorable than Cypherpunk Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Contineum Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Cypherpunk Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Contineum Therapeutics had 1 more articles in the media than Cypherpunk Technologies. MarketBeat recorded 1 mentions for Contineum Therapeutics and 0 mentions for Cypherpunk Technologies. Contineum Therapeutics' average media sentiment score of 0.00 equaled Cypherpunk Technologies'average media sentiment score.

Company	Overall Sentiment
Contineum Therapeutics	Neutral
Cypherpunk Technologies	Neutral

Contineum Therapeutics has a beta of 0.89, indicating that its stock price is 11% less volatile than the broader market. Comparatively, Cypherpunk Technologies has a beta of -0.02, indicating that its stock price is 102% less volatile than the broader market.

Cypherpunk Technologies has lower revenue, but higher earnings than Contineum Therapeutics. Cypherpunk Technologies is trading at a lower price-to-earnings ratio than Contineum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Contineum Therapeutics	$50M	8.62	-$59.98M	-$1.95	N/A
Cypherpunk Technologies	N/A	N/A	$4.82M	-$0.02	N/A

Contineum Therapeutics' return on equity of -27.09% beat Cypherpunk Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Contineum Therapeutics	N/A	-27.09%	-25.64%
Cypherpunk Technologies	N/A	-48.33%	-42.21%

Summary

Contineum Therapeutics beats Cypherpunk Technologies on 10 of the 13 factors compared between the two stocks.

Get Cypherpunk Technologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CYPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CYPH vs. The Competition

Export

Metric	Cypherpunk Technologies	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$55.23M	$3.34B	$6.48B	$11.99B
Dividend Yield	N/A	2.30%	2.67%	5.58%
P/E Ratio	-35.39	18.61	23.69	23.74
Price / Sales	N/A	299.45	514.83	109.27
Price / Cash	N/A	51.45	26.99	37.25
Price / Book	0.39	8.04	10.43	6.78
Net Income	$4.82M	$23.89M	$3.57B	$337.51M
7 Day Performance	-40.49%	-3.28%	0.27%	-2.34%
1 Month Performance	-40.49%	2.78%	3.25%	1.88%
1 Year Performance	72.48%	36.03%	22.24%	25.55%

Cypherpunk Technologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CYPH Cypherpunk Technologies	0.4306 of 5 stars	$0.71 +36.5%	N/A	+80.2%	$55.23M	N/A	N/A	40	Gap Up High Trading Volume
FDMT 4D Molecular Therapeutics	2.6695 of 5 stars	$10.01 +5.0%	$29.88 +198.5%	+98.6%	$498.19M	$85.21M	N/A	120
ARVN Arvinas	2.5268 of 5 stars	$7.74 +0.5%	$15.42 +99.2%	-5.0%	$496.81M	$89.40M	N/A	420
KYTX Kyverna Therapeutics	2.5003 of 5 stars	$7.95 +1.7%	$30.00 +277.4%	+127.4%	$475.42M	N/A	N/A	96	Gap Up
PRTA Prothena	2.9735 of 5 stars	$9.25 +3.7%	$23.75 +156.8%	+58.2%	$466.99M	$9.68M	N/A	130	Positive News Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CYPH) was last updated on 6/9/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cypherpunk Technologies (CYPH) Competitors

CYPH vs. FDMT, ARVN, KYTX, PRTA, and CTNM

How does Cypherpunk Technologies compare to 4D Molecular Therapeutics?

Summary

How does Cypherpunk Technologies compare to Arvinas?

Summary

How does Cypherpunk Technologies compare to Kyverna Therapeutics?

Summary

How does Cypherpunk Technologies compare to Prothena?

Summary

How does Cypherpunk Technologies compare to Contineum Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYPH vs. The Competition

Cypherpunk Technologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cypherpunk Technologies (CYPH) Competitors

CYPH vs. FDMT, ARVN, KYTX, PRTA, and CTNM

How does Cypherpunk Technologies compare to 4D Molecular Therapeutics?

Do insiders & institutionals have more ownership in FDMT or CYPH?

Which has more volatility and risk, FDMT or CYPH?

Which has preferable earnings & valuation, FDMT or CYPH?

Is FDMT or CYPH more profitable?

Does the media refer more to FDMT or CYPH?

Do analysts rate FDMT or CYPH?

Summary

How does Cypherpunk Technologies compare to Arvinas?

Do institutionals & insiders have more ownership in CYPH or ARVN?

Which has more risk and volatility, CYPH or ARVN?

Is CYPH or ARVN more profitable?

Do analysts rate CYPH or ARVN?

Does the media refer more to CYPH or ARVN?

Which has higher earnings and valuation, CYPH or ARVN?

Summary

How does Cypherpunk Technologies compare to Kyverna Therapeutics?

Which has more volatility and risk, KYTX or CYPH?

Is KYTX or CYPH more profitable?

Does the media favor KYTX or CYPH?

Do analysts prefer KYTX or CYPH?

Which has higher valuation & earnings, KYTX or CYPH?

Do institutionals & insiders hold more shares of KYTX or CYPH?

Summary

How does Cypherpunk Technologies compare to Prothena?

Which has stronger earnings & valuation, CYPH or PRTA?

Do insiders & institutionals hold more shares of CYPH or PRTA?

Do analysts rate CYPH or PRTA?

Which has more volatility and risk, CYPH or PRTA?

Does the media prefer CYPH or PRTA?

Is CYPH or PRTA more profitable?

Summary

How does Cypherpunk Technologies compare to Contineum Therapeutics?

Do insiders and institutionals believe in CTNM or CYPH?

Do analysts prefer CTNM or CYPH?

Does the media favor CTNM or CYPH?

Which has more volatility and risk, CTNM or CYPH?

Which has preferable earnings & valuation, CTNM or CYPH?

Is CTNM or CYPH more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYPH vs. The Competition

Cypherpunk Technologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools